Ameriprise
GBIO

Ameriprise’s Generation Bio GBIO Stock Holding History

Ameriprise’s Portfolio GBIO Stock Details GBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,427
Closed -$35.3K – 4113
2024
Q3 		$35.3K Sell
1,427
-350
-20% -$9.26K ﹤0.01% 3896
2024
Q2 		$50.1K Buy
+1,777
New +$57.7K ﹤0.01% 3815
2023
Q1 		– Sell
-1,362
Closed -$53K – 3979
2022
Q4 		$53K Sell
1,362
-7
-0.5% -$368 ﹤0.01% 3859
2022
Q3 		$72K Buy
+1,369
New +$85.6K ﹤0.01% 3868
2021
Q4 		– Sell
-3,164
Closed -$793K – 3996
2021
Q3 		$793K Buy
3,164
+920
+41% +$220K ﹤0.01% 3254
2021
Q2 		$604K Buy
2,244
+192
+9% +$57.4K ﹤0.01% 3391
2021
Q1 		$584K Sell
2,052
-429
-17% -$137K ﹤0.01% 3342
2020
Q4 		$703K Buy
2,481
+510
+26% +$164K ﹤0.01% 3230
2020
Q3 		$609K Sell
1,971
-546
-22% -$131K ﹤0.01% 3178
2020
Q2 		$529K Buy
+2,517
New +$561K ﹤0.01% 3179

Other funds holding GBIO

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise's GBIO Position: Q4 2024 in Review

Ameriprise sold out of Generation Bio (GBIO) in Q4 2024, closing a stake of 1,427 shares — an estimated $35.3K sold.

Ameriprise first reported a position in GBIO in Q2 2020 and held it in 10 quarters. The position peaked at $793K in Q3 2021. 78 funds tracked by Wall St. Rank hold GBIO as of Q4 2024.

  • Ameriprise reported no remaining Generation Bio position as of Q4 2024 after selling out during the quarter.
  • Ameriprise sold 1,427 Generation Bio shares in Q4 2024, an estimated $35.3K.
  • Ameriprise first reported a position in Generation Bio in Q2 2020 and held it in 10 quarters.
  • Ameriprise's Generation Bio position peaked at $793K in Q3 2021.
  • 78 funds tracked by Wall St. Rank held Generation Bio as of Q4 2024.

Based on Ameriprise's 13F filing for Q4 2024, filed 14 Feb 2025.